The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
Open accessThe DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index.
Abstract
The nongenetic mechanisms required to control tumor phenotypic plasticity and shape drug‐resistance remain unclear. We show here that the Aryl hydrocarbon Receptor (AhR) transcription factor directly regulates the gene expression program associated with the acquisition of resistance to BRAF inhibitor (BRAFi) in melanoma. In addition, we show in melanoma cells that canonical activation of AhR mediates the activation of the SRC pathway and promotes the acquisition of an invasive and aggressive resistant phenotype to front‐line BRAFi treatment in melanoma. This nongenetic reprogramming identifies a clinically compatible approach to reverse BRAFi resistance in melanoma. Using a preclinical BRAFi‐resistant PDX melanoma model, we demonstrate that SRC inhibition with dasatinib significantly re‐sensitizes melanoma cells to BRAFi. Together we identify the AhR/SRC axis as a new therapeutic vulnerability to trigger resistance and warrant the introduction of SRC inhibitors during the course of the treatment in combination with front‐line therapeutics to delay BRAFi resistance. This study reports that the AhR/SRC axis constitutes a therapeutic vulnerability in BRAFi‐resistant melanoma. This study reports that the AhR/SRC axis constitutes a therapeutic vulnerability in BRAFi‐resistant melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“SRC activation has been also implicated in innate or acquired resistance to targeted drugs, such as cetuximab in KRAS mutant CRC [32] or BRAFi in BRAFV600E melanoma patients [33, 34]”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [34]
The cited source says what the claim attributes to it.
In the citing paper
“Our hypothesis is also further reinforced by published reports in BRAFV600E melanoma that showed activation of the SRC pathway by Aryl hydrocarbon Receptor (AhR) promotes the acquisition of an invasive and aggressive phenotype resistant to front-line BRAF inhibitors [34].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Cited by
Functions of the aryl hydrocarbon receptor (AHR) beyond the canonical AHR/ARNT signaling pathway
Sondermann, N. C., Faßbender, S., Hartung, F., Hätälä, A. M., Rolfes, K. M., Vogel, C. F. A., & Haarmann-Stemmann, T. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115371 · Cited by 181
The complex biology of aryl hydrocarbon receptor activation in cancer and beyond
Opitz, C. A., Holfelder, P., Prentzell, M. T., & Trump, S. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115798 · Cited by 118
The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation
Polonio, C. M., McHale, K. A., Sherr, D. H., Rubenstein, D., & Quintana, F. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01172-x · Cited by 115
“In particular, AHR inhibitors should target the AHR in malignant cells, where it controls invasiveness, stemness and immunosuppressive genes 250,257,305,306 , and also target the AHR in immune cells, where it promotes immunosuppressive phenotypes 255,307,308 .”
The aryl hydrocarbon receptor: structure, signaling, physiology and pathology
Coumoul, X., Barouki, R., Esser, C., Haarmann‐Stemmann, T., Lawrence, B. P., Lehmann, J., Moura‐Alves, P., Murray, I. A., Opitz, C. A., Perdew, G. H., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02500-8 · Cited by 120
Malignant Melanoma: An Overview, New Perspectives, and Vitamin D Signaling
Slominski, R. M., Kim, T., Janjetović, Z., Brożyna, A. A., Podgórska, E., Dixon, K. M., Mason, R. S., Tuckey, R. C., Sharma, R., Crossman, D. K., et al. (2024) · Cancers · doi:10.3390/cancers16122262 · Cited by 86
Metadata
- Authors
- Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M., & Corre, S.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- VIB-KU Leuven Center for Cancer Biology (BE)
- Corresponding author
- Galibert, Marie‐Dominique
- Corre, Sébastien
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2022-10-28
- Volume
- 14
- Issue
- 12
- Pages
- e15677-e15677
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC9728058
- OpenAlex
- W4307492590
- Cited by
- 26
- References
- 87
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 4
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Association Recherche Contre le Cancer (PGA1*20160203868)
- Centre National de la Recherche Scientifique
- FHU CAMIn‐CHU RENNES
- Institut National de la Santé et de la Recherche Médicale
- Institut National Du Cancer (ENV201308, ENV201603)
- Ligue Contre le Cancer
- Stichting Tegen Kanker (2016‐054)
- Université de Rennes 1
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- aryl hydrocarbon receptor, BRAF inhibitor resistance, melanoma, dasatinib, therapeutic vulnerabilities, transcriptional reprogramming, patient-derived xenografts
- MeSH terms
- Dasatinib, Humans, Melanoma, Phenotype, Receptors, Aryl Hydrocarbon, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma. https://app.cochat.ai/papers/10.15252/emmm.202215677
- The paper
- Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M., & Corre, S. (2022). The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202215677
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.